Visit https://www.peervoice.com/EAW860 to view the entire programme with slides. After completing “Martin Metz, MD - Bringing Chronic Spontaneous Urticaria Under Control: Available and Anticipated Strategies for Escalating Treatment”, participants will be able to: Recognise unmet needs and burdens experienced by patients living with inadequately controlled chronic spontaneous urticaria (CSU); Provide appropriate, individualised treatment to patients with CSU whose symptoms are inadequately controlled with second-generation H1-antihistamines; and Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatment approaches (such as BTK inhibitors) in the management of CSU.

Visit https://www.peervoice.com/SDS860 to view the entire programme with slides. After completing “Thomas Dörner, MD - B-Cell Depletion for Autoimmune Rheumatic Diseases: Expert Perspectives of This Mechanistic Therapeutic Approach in Clinical Context”, participants will be able to: Explain the impact of suboptimal treatment of autoimmune rheumatic diseases on patient outcomes; Discuss the mechanistic role of B cells in the pathophysiology of autoimmune rheumatic diseases; Explain why—despite suboptimal results with established B-cell–targeting therapies in autoimmune rheumatic diseases such as Sjögren’s disease, systemic lupus erythematosus (SLE), and lupus nephritis—B-cell–targeting still holds therapeutic promise; and Identify B-cell–targeting therapies currently being investigated for autoimmune rheumatic diseases and their methods for achieving B-cell depletion.

Visit https://www.peervoice.com/WWE860 to view the entire programme with slides. After completing “Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG”, participants will be able to:

Visit https://www.peervoice.com/DSN860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis”, participants will be able to: Explain how the immunological processes underpinning the pathophysiology of generalised myasthenia gravis (gMG) are targeted by the novel mechanisms of action of emerging therapies; Discuss key characteristics of currently available targeted therapies for gMG with particular reference to potential benefits and limitations; and Evaluate how specific patient factors can impact individualised treatment plans.

Visit https://www.peervoice.com/JGN860 to view the entire programme with slides. After completing “Stephen Jolles, MRCP, FRCPath, PhD - The Many Faces of Primary Immunodeficiencies: Exploring the Plethora of Possibilities Impacting Patient-Integrated Care”, participants will be able to: Recognise the need for an early and accurate diagnosis of primary immunodeficiency diseases (PID); Differentiate between the clinical presentation of infectious and non-infectious manifestations of PID; Use patient factors, clinical features and laboratory testing to facilitate an effective approach to a timely and accurate diagnosis of PID; and Propose an individualised approach to patient-integrated care of PID that optimises therapeutic and management needs of patients and clinicians.

Visit https://www.peervoice.com/VWE860 to view the entire programme with slides. After completing “Janet Pope, MD, MPH, FRCPC - Understanding the Relevance of Rheumatoid Factor Titers in Rheumatoid Arthritis: From Prognosis to Treatment”, participants will be able to: Recognize rheumatoid factor (RF) as a poor prognostic marker in rheumatoid arthritis (RA); Explain how RF may impact serum drug levels and response to biologic therapy; and Evaluate the latest data with biologic therapies showcasing clinical outcomes according to RF titers.

Visit https://www.peervoice.com/YBG860 to view the entire programme with slides. After completing “Jan Dutz, MD, FRCPC - Clinical Updates on Targeting IL-17 in Rheumatic Diseases: Striking at the Heart of Inflammatory Processes in PsA and axSpA”, participants will be able to: Discuss unmet needs in the management of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Evaluate the evidence with new targeted therapies for PsA and axSpA; and Outline the clinical implications with new therapies for the management of patients with PsA and axSpA.

Visit https://www.peervoice.com/QQB860 to view the entire programme with slides. After completing “Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization”, participants will be able to: Describe the various cancer risks in adults that have been linked to human papillomavirus (HPV) infection; Discuss the latest clinical evidence with HPV vaccines; Discuss HPV prevention measures and how nurses can integrate HPV prevention in their clinical practice; and Outline nursing strategies to improve HPV vaccination rates in adults through multidisciplinary collaboration.

Visit https://www.peervoice.com/DPR860 to view the entire programme with slides. After completing “Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care”, participants will be able to: Discuss how technology has been used to optimise care of chronic diseases; Recognise the needs for simplifying the management of immunoglobulin therapy using device and digital technologies; and Identify technologies that are in development to support patient-integrated care for those requiring immunoglobulin therapy and key considerations for their implementation.

Visit https://www.peervoice.com/SGG860 to view the entire programme with slides. After completing “Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey”, participants will be able to: Identify patient and antiretroviral therapy (ART) characteristics that may influence decisions on which ART regimen to initiate in people with HIV at initial diagnosis; Translate the clinical data on the impact of ART on the risk of birth defects in context of current clinical recommendations for viral suppression of HIV in pregnant individuals; Use the benefits and limitations of long-acting injectable antiretroviral therapy (LAI-ART) to identify which people living with HIV may be appropriate for LAI-ART; and Explain the impact of age-related changes such as menopause and cognitive decline on the clinical management of people living with HIV.

Visit https://www.peervoice.com/THE860 to view the entire programme with slides. After completing “John K. Marshall, MD, MSc, FRCPC, AGAF, CAGF - Targeting IL-23 in Ulcerative Colitis: Can We Raise the Bar in Disease Control for Our Patients?”, participants will be able to: Explain the mechanism of action of anti-IL-23 therapies in ulcerative colitis (UC); Evaluate the latest clinical evidence with anti-IL-23 agents in UC; Discuss evolving treatment goals and definitions of remission in patients with UC; and Define the potential role of anti-IL-23 agents in patients with UC, based on the latest evidence.

Visit https://www.peervoice.com/TDQ860 to view the entire programme with slides. After completing “Irina Turchin, MD, FRCPC, DABD - Unraveling the Pathophysiology of Moderate-to-Severe Atopic Dermatitis: Clinical Implications for Health”, participants will be able to: Describe the epidemiology of atopic dermatitis (AD), including its prevalence, risk factors, and associated comorbidities; Outline the physiology and heterogeneity of moderate-to-severe AD; and Identify the burden of moderate-to-severe AD, including the short- and long-term impact on patients’ quality of life, physical, and psychosocial health.

Visit https://www.peervoice.com/PBJ860 to view the entire programme with slides. After completing “Sorena Kiani, MBPhD, FRCP, FRCPath - Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Targeted Prophylactic Therapy?”, participants will be able to: Outline the latest treatment guidelines for prophylactic treatment of hereditary angioedema (HAE) and the rationale for why attenuated androgens are recommended second-line; Identify current therapies for first-line long-term prophylaxis of HAE; and Propose how to optimally manage the transition of patients with HAE from attenuated androgens to alternative prophylactic agents.

Visit https://www.peervoice.com/ZJB860 to view the entire programme with slides. After completing “Michael W. Nicolle, MD, FRCPC, D.Phil - Complement-Directed Therapy for Generalized Myasthenia Gravis: From Bench to Bedside”, participants will be able to: Apply the latest evidence with complement-directed therapy to the management of mild-to-moderate generalized myasthenia gravis (gMG) in the clinic; and Discuss the evidence with emerging complement-directed therapies for gMG.

Visit https://www.peervoice.com/NTE860 to view the entire programme with slides. After completing “Kurt G. Naber, MD, PhD - How Are We Tackling the Nemesis of Drug-Resistant Uropathogens?”, participants will be able to: Discuss the challenges of treating acute and recurrent urinary tract infections (UTIs) caused by resistant uropathogens in uncomplicated UTIs; Apply current guidance to optimise treatment of drug-resistant uropathogens in uncomplicated UTIs; and Why to incorporate new and emerging strategies for treating uncomplicated sporadic or recurrent UTIs into clinical practice in accordance with the principles of good antimicrobial prescribing.

Visit https://www.peervoice.com/ZFS860 to view the entire programme with slides. After completing “Allison Agwu, MD, ScM - Me the Clinician; Me the Mom: Why Vaccinate Children Against COVID-19?”, participants will be able to: Describe the potential benefits of vaccinating children against COVID-19; Summarise the key concerns that parents may have regarding vaccinating children against COVID-19; and Apply approaches to improve parental communication and education regarding the importance of vaccinating children against COVID-19.

Visit https://www.peervoice.com/ZTV860 to view the entire programme with slides. After completing “C. Buddy Creech, MD, MPH - Children and the COVID Vaccine”, participants will be able to: Summarise the efficacy and safety profiles of COVID-19 vaccines currently approved for use in children; Describe the implications associated with children becoming infected with COVID-19; and Apply practical approaches to parental collaboration and education on the importance and value of preventing COVID-19 in order to facilitate COVID-19 vaccination uptake in children.

Visit https://www.peervoice.com/YGK860 to view the entire programme with slides. After completing “John Papastergiou, BScPhm, PhDc - Human Papillomavirus Head and Neck Cancers: Improving Outcomes in Adults Through Vaccination”, participants will be able to:

Visit https://www.peervoice.com/YEJ860 to view the entire programme with slides. After completing “Christine Palmay, HBArtSci, MD, CCFP, FCFP - The Case for Herpes Zoster Vaccination: Addressing Care Gaps in Immunocompromised Individuals”, participants will be able to: Describe the burden of herpes zoster (HZ) infection for immunocompromised patients who are at increased risk of infection; List the clinical evidence and recommendations against HZ in immunocompromised patients; and Formulate appropriate immunization plans for immunocompromised patients to maximize protection against HZ.

Visit https://www.peervoice.com/JYS860 to view the entire programme with slides. After completing “Remo Panaccione, MD, FRCPC / Brian Bressler, MD, MS, FRCPC - It's About Time: Why We Need to Address Bowel Urgency in Patients With Ulcerative Colitis”, participants will be able to: Explain the burden of bowel urgency and its impact on quality of life in patients with ulcerative colitis; Evaluate the correlation of bowel urgency with key clinical outcomes; and Outline tools and strategies to facilitate the discussion of bowel urgency with patients with UC and its assessment in the clinic.